Patents by Inventor John Ridden

John Ridden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11484512
    Abstract: The present invention relates to a composition for use in the treatment of onychomycosis and/or tinea pedis, the composition comprising a polymer capable of forming nanoparticles and terbinafine, or derivative or salt thereof, wherein the nanoparticles are formed with and/or in the presence of terbinafine, or derivative or salt thereof and wherein the composition is administered topically to provide a daily dose to an infected area in the range of about 5 ?g to about 50 ?g of terbinafine. The invention also relates to a combination of the composition and a liquid dispensing device for dispensing a pre-defined quantity of the composition to a user's toes and/or inter-digital spaces and/or front of the foot.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: November 1, 2022
    Assignee: Blueberry Therapeutics Limited
    Inventors: John Ridden, Christine Caroline Ridden, David Cook, Julie Cook
  • Publication number: 20220133640
    Abstract: The present invention relates nanoparticles formed of a polymer and an antifungal agent, wherein the polymer is selected from the group consisting of linear or branched or cyclic polymonoguanide/polyguanidine, polybiguanide, analogues or derivatives thereof, or mixtures thereof. The nanoparticles are particularly suited for the treatment of fungal nail or skin infections.
    Type: Application
    Filed: October 27, 2021
    Publication date: May 5, 2022
    Inventors: John RIDDEN, Michael DAVIES, Liam GOOD
  • Patent number: 11185511
    Abstract: The present invention relates to a topical composition (and methods of producing the such compositions) for the treatment of a fungal infection comprising a polymer capable of forming nanoparticles and an antifungal agent. The invention also relates to novel uses of polyhexamethylene biguanide.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: November 30, 2021
    Assignee: BLUEBERRY THERAPEUTICS LIMITED
    Inventors: John Ridden, Michael Davies, Liam Good
  • Publication number: 20210275506
    Abstract: The present invention relates to compositions for use in the treatment of a dermatological condition, comprising a polymer capable of forming nanoparticles an anti-inflammatory and/or analgesic agent. The composition is particularly suited to the treatment of acne and/or atopic dermatitis. The invention also relates to novel uses of polyhexamethylene biguanide.
    Type: Application
    Filed: July 3, 2019
    Publication date: September 9, 2021
    Inventors: Christine Ridden, John Ridden, David Cook
  • Publication number: 20210259981
    Abstract: The present invention relates to compositions for use in the treatment or management of inflammation and/or pain, comprising a polymer capable of forming nanoparticles an anti-inflammatory and/or analgesic agent. The invention also relates to novel uses of polyhexamethylene biguanide.
    Type: Application
    Filed: July 3, 2019
    Publication date: August 26, 2021
    Inventors: Christine Ridden, John Ridden, David Cook
  • Publication number: 20200206160
    Abstract: The present invention relates to a composition for use in the treatment of a fungal infection comprising a polymer capable of forming nanoparticles and terbinafine, or derivative or salt thereof, wherein the nanoparticles are formed with and/or in the presence of terbinafine, or derivative or salt thereof, and where the composition comprises: a) a ratio of terbinafine, or derivative or salt thereof, to polymer in the range of about 1:2 to 1:4; and b) up to about 30% (v/v) alcohol. The composition is particularly suited as a topical treatment for fungal nail or skin infections. The invention also relates to methods of producing such compositions and combinations which can be used to produce said same.
    Type: Application
    Filed: March 24, 2017
    Publication date: July 2, 2020
    Inventors: John Ridden, Christine Caroline Ridden, David Cook
  • Publication number: 20200155482
    Abstract: The present invention relates to a composition for use in the treatment of onychomycosis and/or tinea pedis, the composition comprising a polymer capable of forming nanoparticles and terbinafine, or derivative or salt thereof, wherein the nanoparticles are formed with and/or in the presence of terbinafine, or derivative or salt thereof and wherein the composition is administered topically to provide a daily dose to an infected area in the range of about 5 ?g to about 50 ?g of terbinafine. The invention also relates to a combination of the composition and a liquid dispensing device for dispensing a pre-defined quantity of the composition to a user's toes and/or inter-digital spaces and/or front of the foot.
    Type: Application
    Filed: June 28, 2018
    Publication date: May 21, 2020
    Inventors: John Ridden, Christine Caroline Ridden, David Cook, Julie Cook
  • Patent number: 10517835
    Abstract: The present invention relates to a composition comprising nanoparticles formed of a polymer and terbinafine, wherein the nanoparticles comprise particles in the range of 0.5 to 5 nm and/or in the range of 150 to 250 nm. Such compositions are particularly suited, but not limited, to the treatment of fungal nail infections.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: December 31, 2019
    Assignee: Bueberry Therapeutics Limited
    Inventors: John Ridden, Christine Caroline Ridden, David Cook
  • Patent number: 10293024
    Abstract: A compound comprising the amino acid sequence HKSRALLIFQKIMWLRRQ (SEQ ID No: 1) or comprising a part of said amino acid sequence of 7 or more amino acids, or comprising a variant of said amino acid sequence or said part thereof in which from 1 to 5 amino acids have been altered, wherein the compound binds to MAP kinase p38?. The compounds are useful in binding to and inhibiting MAP kinase p38?, and are useful as research tools, in drug discovery, medicine, particularly for treating inflammatory conditions.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: May 21, 2019
    Assignee: Blueberry Therapeutics Limited
    Inventor: John Ridden
  • Publication number: 20180193281
    Abstract: The present invention relates to a composition comprising nanoparticles formed of a polymer and terbinafine, wherein the nanoparticles comprise particles in the range of 0.5 to 5 nm and/or in the range of 150 to 250 nm. Such compositions are particularly suited, but not limited, to the treatment of fungal nail infections.
    Type: Application
    Filed: July 6, 2016
    Publication date: July 12, 2018
    Inventors: John Ridden, Christine Caroline Ridden, David Cook
  • Publication number: 20160206567
    Abstract: The present invention relates to a topical composition (and methods of producing the such compositions) for the treatment of a fungal infection comprising a polymer capable of forming nanoparticles and an antifungal agent. The invention also relates to novel uses of polyhexamethylene biguanide.
    Type: Application
    Filed: September 25, 2014
    Publication date: July 21, 2016
    Inventors: John RIDDEN, Michael DAVIES, Liam GOOD
  • Publication number: 20160193281
    Abstract: A compound comprising the amino acid sequence HKSRALLIFQKIMWLRRQ (SEQ ID No: 1) or comprising a part of said amino acid sequence of 7 or more amino acids, or comprising a variant of said amino acid sequence or said part thereof in which from 1 to 5 amino acids have been altered, wherein the compound binds to MAP kinase p38?. The compounds are useful in binding to and inhibiting MAP kinase p38?, and are useful as research tools, in drug discovery, medicine, particularly for treating inflammatory conditions.
    Type: Application
    Filed: August 15, 2014
    Publication date: July 7, 2016
    Inventor: John Ridden
  • Publication number: 20160089393
    Abstract: The present invention provides compositions and methods for sensitizing a bacterium to an antibacterial the method comprising the step of exposing the bacterium, in the presence of an entry-promoting agent, to an agent that inhibits antibacterial resistance. Methods for killing an antibacterial-resistant bacterium comprising the step of exposing the bacterium, in the presence of an entry-promoting agent, to an agent that inhibits antibacterial resistance and exposing the bacterium to an antibacterial are also provided. The methods may also include the step of identifying the bacterium and the antibacterial resistance profile of the bacterium and tailoring the methods accordingly. Exemplary entry promoting agents provided are polyhexamethylene biguanide (PHMB) and polyhexamethyleneguanide (PHMG). Exemplary agents that inhibit antibacterial resistance are agents that bindto and inhibit antibacterial-resistance determinants such as beta-lactamases, PBP2a, NDM-1 and Vim2.
    Type: Application
    Filed: April 17, 2014
    Publication date: March 31, 2016
    Inventors: John Ridden, Liam Good
  • Publication number: 20050106638
    Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.
    Type: Application
    Filed: August 30, 2004
    Publication date: May 19, 2005
    Applicant: Pfizer Inc.
    Inventors: Dinah Parums, Stephen Phillips, John Ridden
  • Patent number: 6794192
    Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: September 21, 2004
    Assignee: Pfizer Inc.
    Inventors: Dinah Parums, Stephen Charles Phillips, John Ridden
  • Publication number: 20030040041
    Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.
    Type: Application
    Filed: June 28, 2001
    Publication date: February 27, 2003
    Inventors: Dinah Parums, Stephen Charles Phillips, John Ridden